- Home
- SOUN vs PVLA Comparison
SOUN vs PVLA Comparison
Compare SOUN & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOUN | PVLA |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.9B |
| IPO Year | 2021 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SOUN | PVLA |
|---|---|---|
| Price | $4.38 | $127.26 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 16 |
| Target Price | $12.57 | ★ $228.93 |
| AVG Volume (30 Days) | ★ 11.9M | 187.1K |
| Earning Date | 11-05-2026 | 11-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | 52.62 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $42,810,000.00 |
| Revenue This Year | $73.87 | N/A |
| Revenue Next Year | $32.87 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.28 |
| 52 Week Low | $4.20 | $71.55 |
| 52 Week High | $18.36 | $161.38 |
Technical Indicators
Market Signals| Indicator | SOUN | PVLA |
|---|---|---|
| Relative Strength Index (RSI) | 23.00 | 41.52 |
| Support Level | N/A | $119.42 |
| Resistance Level | $6.18 | $136.35 |
| Average True Range (ATR) | 0.24 | 6.61 |
| MACD | -0.05 | 0.33 |
| Stochastic Oscillator | 1.99 | 37.20 |
Price Performance
Historical ComparisonAbout SOUN SoundHound AI Inc
SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.
About PVLA Palvella Therapeutics Inc.
Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company whose vision is to become the rare disease biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no FDA-approved therapies. Its product candidate, QTORIN 3.9% rapamycin anhydrous gel, is currently in clinical development for microcystic lymphatic malformations and cutaneous venous malformations. It operates in single segment.